Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus.

Cantarelli C, Guglielmo C, Hartzell S, Salem FE, Andrighetto S, Gazivoda VP, Fiaccadori E, La Manna G, Zaza G, Leventhal J, Tassiulas I, Cravedi P.

Front Immunol. 2019 Nov 20;10:2695. doi: 10.3389/fimmu.2019.02695. eCollection 2019.

2.

Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice.

Kyrmizi I, Ioannou M, Hatziapostolou M, Tsichlis PN, Boumpas DT, Tassiulas I.

J Leukoc Biol. 2013 Oct;94(4):751-7. doi: 10.1189/jlb.0113039. Epub 2013 Jul 29.

3.

Gene network analysis of bone marrow mononuclear cells reveals activation of multiple kinase pathways in human systemic lupus erythematosus.

Nakou M, Bertsias G, Stagakis I, Centola M, Tassiulas I, Hatziapostolou M, Kritikos I, Goulielmos G, Boumpas DT, Iliopoulos D.

PLoS One. 2010 Oct 14;5(10):e13351. doi: 10.1371/journal.pone.0013351. Erratum in: PLoS One. 2013;8(4). doi:10.1371/annotation/d68d4b94-c44a-4893-83f4-55a8a626990f.

4.

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.

Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT.

Ann Rheum Dis. 2010 Dec;69(12):2074-82. doi: 10.1136/ard.2010.130476. Epub 2010 Aug 19.

PMID:
20724309
5.

Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures.

Nakou M, Knowlton N, Frank MB, Bertsias G, Osban J, Sandel CE, Papadaki H, Raptopoulou A, Sidiropoulos P, Kritikos I, Tassiulas I, Centola M, Boumpas DT.

Arthritis Rheum. 2008 Nov;58(11):3541-9. doi: 10.1002/art.23961.

6.

'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages.

Wang L, Tassiulas I, Park-Min KH, Reid AC, Gil-Henn H, Schlessinger J, Baron R, Zhang JJ, Ivashkiv LB.

Nat Immunol. 2008 Feb;9(2):186-93. Epub 2007 Dec 16.

PMID:
18084294
7.

Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages.

Tassiulas I, Park-Min KH, Hu Y, Kellerman L, Mevorach D, Ivashkiv LB.

Hum Immunol. 2007 Mar;68(3):156-64. Epub 2007 Jan 8.

8.

Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors.

Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB.

Nat Immunol. 2004 Nov;5(11):1181-9. Epub 2004 Oct 3.

PMID:
15467722
9.

IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis.

Sharif MN, Tassiulas I, Hu Y, Mecklenbräuker I, Tarakhovsky A, Ivashkiv LB.

J Immunol. 2004 May 15;172(10):6476-81.

10.

Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.

Takada K, Danning CL, Kuroiwa T, Schlimgen R, Tassiulas IO, Davis JC Jr, Yarboro CH, Fleisher TA, Boumpas DT, Illei GG.

Ann Rheum Dis. 2003 Nov;62(11):1112-5.

11.

Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis.

Ji JD, Tassiulas I, Park-Min KH, Aydin A, Mecklenbrauker I, Tarakhovsky A, Pricop L, Salmon JE, Ivashkiv LB.

J Exp Med. 2003 Jun 2;197(11):1573-83.

12.

Can SOCS make arthritis better?

Ivashkiv LB, Tassiulas I.

J Clin Invest. 2003 Mar;111(6):795-7. No abstract available.

13.

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA.

Clin Nephrol. 1999 Aug;52(2):67-75.

PMID:
10480216
14.

Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis.

Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT.

Hum Immunol. 1999 Jun;60(6):479-91.

PMID:
10408797
15.

High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.

Davis JC Jr, Fessler BJ, Tassiulas IO, McInnes IB, Yarboro CH, Pillemer S, Wilder R, Fleisher TA, Klippel JH, Boumpas DT.

J Rheumatol. 1998 Sep;25(9):1694-704.

PMID:
9733448
16.

Angiotensin I converting enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD genotype in African American patients.

Tassiulas IO, Aksentijevich I, Salmon JE, Kim Y, Yarboro CH, Vaughan EM, Davis JC, Scott DL, Austin HA, Klippel JH, Balow JE, Gourley MF, Boumpas DT.

Clin Nephrol. 1998 Jul;50(1):8-13.

PMID:
9710341
17.

Lupus nephritis.

Davis JC, Tassiulas IO, Boumpas DT.

Curr Opin Rheumatol. 1996 Sep;8(5):415-23. Review.

PMID:
8941444

Supplemental Content

Loading ...
Support Center